文章导读：在APSAL大会第四天，Michael P. Manns教授做了题为Advances in Hepatitis C Infection的大会报告。他提出丙型病毒性肝炎已经可以根据基因型及早期治疗反应行个体化治疗。
Michael P. Manns
Medical School of Hannover, Germany
On the fourth day of APASL, Professor Michael P. Manns presented a lecture on advances in hepatitis C infection. He said in recent years, therapy for hepatitis C had been optimized by individualizing of treatment according to genotype and early treatment response. Achieving rapid virological respons (RVR) can shortern the duration of treatment. For all genotype 1 patients early virological response (EVR) has become very important to guide treatment. If they do not achieve EVR, treatment is stopped since success rates are minimal. The final goal of treatment is to achieve sustained virological response (SVR). It has been shown that relapse rates in patients achieving SVR are extremely rare.